Sergio Gilaberte Reyzabal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sergio Gilaberte Reyzabal has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- David Alan Isenberg
Department of Ageing, Rheumatology and Regenerative Medicine, University College London , London
1 shared publication
Latest Publications
- Open Access
- 16 May 2022
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 9, 882891
Differences in the Development of Adverse Infusion Reactions to Rituximab in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis and Non-Hodgkin's Lymphoma-Enigma Variations
It has become clear that rituximab treatment is useful for both B-cell malignancies and autoimmune rheumatic diseases. However this treatment is associated with an increased risk of an allergic reaction. We have reviewed the frequency with which these reactions occur in these different conditions. They appear to be less frequent when rituximab is used to treat rheumatoid arthritis and systemic lupus perhaps because concomitant steroids are invariably given to these patients with the rituximab which is not necessarily the case with the treatment of B-cell malignancies.
- 16 May 2022
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 9, 882891
Open AccessDifferences in the Development of Adverse Infusion Reactions to Rituximab in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis and Non-Hodgkin's Lymphoma-Enigma Variations
It has become clear that rituximab treatment is useful for both B-cell malignancies and autoimmune rheumatic diseases. However this treatment is associated with an increased risk of an allergic reaction. We have reviewed the frequency with which these reactions occur in these different conditions. They appear to be less frequent when rituximab is used to treat rheumatoid arthritis and systemic lupus perhaps because concomitant steroids are invariably given to these patients with the rituximab which is not necessarily the case with the treatment of B-cell malignancies.